Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hofmann

Showing results (291-300 of 309) with videos related to

Pageof 31
Sort By:
European Journal of Applied Physiology|February 1, 2003
Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndromeWolfgang Schobersberger, Peter Schmid, Monika Lechleitner, et al.
JHEP Reports : Innovation in Hepatology|September 23, 2020
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD careWolf Peter Hofmann, Peter Buggisch, Lisa Schubert, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 16, 2025
Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus PanelYestle Kim, Peter Rydqvist, Thomas Ramezani, et al.
Gut|April 12, 2012
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosisRoeland Zoutendijk, Jurrien G P Reijnders, Fabien Zoulim, et al.
Frontiers in Oncology|January 1, 2026
What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based studySelina Becht, Najib Ben Khaled, Simone Schrodi, et al.
Journal of Clinical Medicine|April 3, 2021
Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from GermanyAnne-Christin Beatrice Wilde, Charlotte Lieb, Elise Leicht, et al.
Journal of Gastroenterology and Hepatology|December 10, 2015
Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosisAdriaan J van der Meer, Raoel Maan, Bart J Veldt, et al.
Journal of Hepatology|December 15, 2010
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfectionChristian M Lange, Darius Moradpour, Alexandra Doehring, et al.
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
Hepatology (Baltimore, Md.)|May 13, 2011
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological responseRoeland Zoutendijk, Jurriën G P Reijnders, Ashley Brown, et al.
Pageof 31

Showing results (291-300 of 309) with videos related to

Sort By:
Pageof 31
European Journal of Applied Physiology|February 1, 2003
Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndromeWolfgang Schobersberger, Peter Schmid, Monika Lechleitner, et al.
JHEP Reports : Innovation in Hepatology|September 23, 2020
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD careWolf Peter Hofmann, Peter Buggisch, Lisa Schubert, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 16, 2025
Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus PanelYestle Kim, Peter Rydqvist, Thomas Ramezani, et al.
Gut|April 12, 2012
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosisRoeland Zoutendijk, Jurrien G P Reijnders, Fabien Zoulim, et al.
Frontiers in Oncology|January 1, 2026
What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based studySelina Becht, Najib Ben Khaled, Simone Schrodi, et al.
Journal of Clinical Medicine|April 3, 2021
Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from GermanyAnne-Christin Beatrice Wilde, Charlotte Lieb, Elise Leicht, et al.
Journal of Gastroenterology and Hepatology|December 10, 2015
Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosisAdriaan J van der Meer, Raoel Maan, Bart J Veldt, et al.
Journal of Hepatology|December 15, 2010
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfectionChristian M Lange, Darius Moradpour, Alexandra Doehring, et al.
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
Hepatology (Baltimore, Md.)|May 13, 2011
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological responseRoeland Zoutendijk, Jurriën G P Reijnders, Ashley Brown, et al.
Pageof 31